Delayed puberty, gonadotropin abnormalities and subfertility in male \textit{Padi2}/\textit{Padi4} double knockout mice

Kelly L. Sams\textsuperscript{1}, Chinatsu Mukai\textsuperscript{1}, Brooke A. Marks\textsuperscript{1}, Chitvan Mittal\textsuperscript{1}, Elena Alina Demeter\textsuperscript{2}, Sophie Nelissen\textsuperscript{2}, Jennifer K. Grenier\textsuperscript{3}, Ann E. Tate\textsuperscript{3}, Faraz Ahmed\textsuperscript{3} and Scott A. Coonrod\textsuperscript{1,2*}

Abstract

Background: Peptidylarginine deiminase enzymes (PADs) convert arginine residues to citrulline in a process called citrullination or deimination. Recently, two PADs, PAD2 and PAD4, have been linked to hormone signaling in vitro and the goal of this study was to test for links between PAD2/PAD4 and hormone signaling in vivo.

Methods: Preliminary analysis of \textit{Padi2} and \textit{Padi4} single knockout (SKO) mice did not find any overt reproductive defects and we predicted that this was likely due to genetic compensation. To test this hypothesis, we created a \textit{Padi2/Padi4} double knockout (DKO) mouse model and tested these mice along with wild-type FVB/NJ (WT) and both strains of SKO mice for a range of reproductive defects.

Results: Controlled breeding trials found that male DKO mice appeared to take longer to have their first litter than WT controls. This tendency was maintained when these mice were mated to either DKO or WT females. Additionally, unsexed 2-day old DKO pups and male DKO weanlings both weighed significantly less than their WT counterparts, took significantly longer than WT males to reach puberty, and had consistently lower serum testosterone levels. Furthermore, 90-day old adult DKO males had smaller testes than WT males with increased rates of germ cell apoptosis.

Conclusions: The \textit{Padi2/Padi4} DKO mouse model provides a new tool for investigating PAD function and outcomes from our studies provide the first in vivo evidence linking PADs with hormone signaling.

Keywords: PAD2, PAD4, Citrullination, Hormone signaling, Estrogen receptor, Androgen receptor, Delayed puberty
is regulated by steroid hormone signaling [5–8]. Steroid hormones are essential mediators of many physiological events including reproduction and development [9]. These hormones carry out their effects by binding to their cognate nuclear receptors which, in turn, bind to hormone response DNA elements and regulate transcription via interaction with a wide range of co-regulators and the basal transcriptional machinery. Given the potential links between PADs and steroid hormones and that histones were found to be targeted by PAD4 for citrullination [10], we previously tested whether PAD2 and PAD4 may play a role in estrogen signaling in breast cancer cells by facilitating ER target gene expression via histone citrullination at ER binding sites. Results from our studies found that PAD4 is recruited to the TFF1 promoter (a canonical ERα binding site) in MCF7 cells following E2 treatment leading to citrullination of histone H4 arginine 3 [11]. Additionally, we found that PAD2 interacts with ER in an estrogen-dependent manner and that estrogen (E2) treatment activates PAD2 leading to citrullination of histone H3 arginine 26 (H3Cit26) at ER binding sites [12, 13]. We then demonstrated by ChIP-Seq that ~95% of ER binding sites throughout the genome are citrullinated at H3Cit26 within 5–10 minutes of E2 treatment [14]. We also found that PAD inhibitors potently blocked ER binding at Estrogen Response Elements (EREs) and prevented ER target gene activation [13].

Regarding a potential role for PADs in hormone signaling in males, another group recently found that PAD2 plays a role in androgen receptor (AR) signaling by facilitating nuclear import of AR and promoting AR target gene activation via histone citrullination at AR binding sites in castration resistant prostate cancer cell lines (CRPC; LnCaP and VCaP) [12]. This finding suggests that the role of PADs in regulating hormone-mediated transcription may be broader than we had previously realized.

Recent studies have already begun to document the presence of PAD2 in the testis. For example, Tsuji-Hosokawa et al. showed that PAD2 appears to play an important role in testis development and is specifically expressed in fetal Sertoli cells, and that this expression is regulated by SOX9 a critical mediator of sex determination [15]. Another recent study used PCR, western blotting, and IHC to show that Padi2 is expressed in sperm during the first wave of spermatogenesis and appears to localize to the acrosomal region of the sperm head [16]. There are currently no reports of PAD4 localization to the testes, however, IHC analysis of the testis from the Human Protein Atlas (proteインタラス.org) does show anti-PAD4 staining (moderate intensity) specifically in Leydig cells [6]. Importantly, to date, there have not been any published reports linking PADs to hormone signaling in animal models and this lack of in vivo data has likely limited research into this area.

To address this gap in knowledge, we began testing for links between PADs and hormone signaling in vivo by determining whether Padi2 and Padi4 single knockout (SKO) mouse lines displayed overt reproductive defects. Initial observations with these mice found that both Padi2 and Padi4 SKO mice appear normal with no overt reproductive defects. Given that the amino acid sequence in PAD family members is 59–70% identical, and that Padi genes are closely clustered together at chromosome 1p35–36 in humans and chromosome 4E1 in mice [3, 17], we predicted that the lack of a conspicuous phenotype in the SKO lines was due to genetic compensation by other Padis. In order to test this hypothesis, we generated a Padi2/Padi4 double knockout mouse (DKO) line by deleting Padi4 from our existing Padi2 knockout (P2KO) mouse line using CRISPR/CAS9 technology. We demonstrate that, as opposed to the SKO lines, the Padi2/ Padi4 DKO mice display a range of reproductive defects. Outcomes from our studies focusing on the DKO males show that they display a reduced pup and weanling weight, delayed puberty, reduced testis size, increased rates of apoptosis during spermatogenesis, and altered circulating hormone levels. Our results provide the first in vivo evidence that PADs play a role in male reproduction, potentially via their role in hormone signaling.

**Materials and methods**

**Animals**

All mice used in this work were on an FVB/NJ background and were maintained as inbred homozygous lines. The mice were housed in an AAALAC certified facility, with 12 hours on/off light cycle, temperature control and food and water ad libitum. All procedures were approved by Cornell University’s Animal Care and Use Committee (IACUC) and in compliance with the US National Research Council’s Guide for the Care and Use of Laboratory Animals [18]. Breeding were recorded and lineages tracked with Softmouse Colony Management Software [19]. Euthanasia was performed by CO2 inhalation in accordance with American Veterinary Medical Association approved practice.

**Generation of transgenic single knockout mice**

Padi2-null mice (FVB/N) background were generated using gene trap technology at the Texas A&M Institute for Genomic Medicine [20]. For the gene trap, 163 nucleotides of exon 1 in Padi2 (from the ATG initial codon to intron 1–2) were replaced by the LacZ and Neomycin coding sequence. These mice are genotyped in a multiplex mixture using Padi2 WT and KO specific primers (Table 1).
Padi4-null mice (FVB/NJ background) were generated using Regeneron’s VelociGene technology. The genomic sequence of Padi4 from the ATG initial codon to approximately 100 bp downstream of the TGA stop codon was replaced in frame (with respect to the Padi4 initiation codon) with a Lox-flanked LacZ and neomycin coding sequence. These mice are genotyped using Padi4 primers shown in Table 1.

Generation of Padi2/Padi4 double knockout mice
Padi2-null mice were used for IVF and CRISPR/Cas9 RNA injection was performed at Cornell’s Stem Cell & Transgenic Core Facility. Cas9 mRNA and Padi4 sgRNA targeting Exon 1 of the Padi4 gene were injected into the pronucleus of Padi2 KO embryos and the embryos were cultured to the two-cell stage and transferred into pseudopregnant recipient FVB/NJ female mice [21, 22]. Thirty-nine founders were produced and 13 edited founders were then identified by heteroduplex PCR [23]. Briefly, genomic DNA was extracted from punched ear tissue and evaluated by PCR using the Padi4 primer set noted above. Standard PCR conditions for GoTaq (Promega) were used as follows: 95°C for 5 min; 94°C for 30 s, 59°C for 30 s, 72°C for 30 s for 35 cycles; 72°C for 5 min followed by 5 minutes of denaturation at 95°C. PCR products were loaded onto a 12% polyacrylamide gel. Positive heteroduplex bands were purified and subjected to TA cloning for Sanger sequencing. All 13 edited founders were found to be heterozygous mutants, with 7 founders being identified as having a frameshift mutation either by insertion or deletion. One heterozygous founder with a four-nucleotide deletion was back-crossed to the background Padi2 knockout mice, and their heterozygous offspring were then paired to create a homozygous DKO line (Fig. 1).

Authentication of Padi2/Padi4 double knockout mice
RT-PCR of Padi transcripts
Total RNA was extracted from mouse salivary glands using Tri-Reagent (Molecular Research Center #TR118) and cDNA was created with a High Capacity RNA-to-cDNA Kit (Applied Biosystems #4387406) according to manufacturers’ instructions. PCR amplification was accomplished under standard cycling conditions with GoTaq (Promega #M3001) using primers listed in Table 1. PCR products were run on a 2% agarose gel to confirm the presence or absence of Padi transcripts (Fig. 2a,d; Additional File 1).

PCR of Padi4 locus
Genomic DNA was isolated from ear-punch tissue samples and the Padi4 locus was amplified under standard GoTaq conditions using primers listed in Table 1. PCR products were run on a 2% Agarose gel to confirm the presence or absence of the Padi4 gene (Fig. 2b).

Western blot for PAD2 and PAD4 protein products
Tissue lysate was prepared from splenic tissue and resolved by SDS-PAGE followed by transfer to a PVDF membrane. The membranes were incubated overnight

Table 1: Primers used for genotyping and authentication of DKO mice

| Target            | Sequence (5’ to 3’) | Amplicon (bp) |
|-------------------|---------------------|---------------|
| Genomic DNA       |                     |               |
| Padi2-gDNA (WT)   | CTATTTCCTGGGAGCGACAC| 233           |
|                   | CTCTCTCTGGCTCTCCGTG |               |
| Padi2-gDNA (LacZ-Neo) | GTAAGAAGGATTTGAAAGTG | 312          |
|                   | GTACGGGGATCAAGCTTATG |               |
| Padi4-gDNA        | AGGATCTCTGCCTCTCAC   | 154–160       |
|                   | CTGCGCTGGCACTTAAAGG  |               |
| RT-PCR            |                     |               |
| Padi1             | TGGCCACCTCTGACAAAGA  | 123           |
|                   | GCTTGAAGGCACTAAACTGC |               |
| Padi2             | CAAGATCTCTGCAAATGAGA | 189           |
|                   | ATCATGTTACCAGTTAGGGA |               |
| Padi3             | CGGAGGGGTGACATCATCGAC| 88            |
|                   | AGCATATCAACAGATCGGG  |               |
| GAPDH             | TGTTGCCGGTGGATCTGGA  | 150           |
|                   | TTGCTGTTGAAGTCGAGGAG |               |
| β-actin           | CATCGTAAAGACCCTCTATCCAC | 171       |
|                   | ATGGAGCCACCGATCCAACA |               |

Table 1 Primers used for genotyping and authentication of DKO mice

| Target            | Sequence (5’ to 3’) | Amplicon (bp) |
|-------------------|---------------------|---------------|
| Genomic DNA       |                     |               |
| Padi2-gDNA (WT)   | CTATTTCCTGGGAGCGACAC| 233           |
|                   | CTCTCTCTGGCTCTCCGTG |               |
| Padi2-gDNA (LacZ-Neo) | GTAAGAAGGATTTGAAAGTG | 312          |
|                   | GTACGGGGATCAAGCTTATG |               |
| Padi4-gDNA        | AGGATCTCTGCCTCTCAC   | 154–160       |
|                   | CTGCGCTGGCACTTAAAGG  |               |
| RT-PCR            |                     |               |
| Padi1             | TGGCCACCTCTGACAAAGA  | 123           |
|                   | GCTTGAAGGCACTAAACTGC |               |
| Padi2             | CAAGATCTCTGCAAATGAGA | 189           |
|                   | ATCATGTTACCAGTTAGGGA |               |
| Padi3             | CGGAGGGGTGACATCATCGAC| 88            |
|                   | AGCATATCAACAGATCGGG  |               |
| GAPDH             | TGTTGCCGGTGGATCTGGA  | 150           |
|                   | TTGCTGTTGAAGTCGAGGAG |               |
| β-actin           | CATCGTAAAGACCCTCTATCCAC | 171       |
|                   | ATGGAGCCACCGATCCAACA |               |
with primary antibodies diluted in 1% BSA-TBST at 4°C using the following concentrations: anti-PAD4 (1:1000; Abcam; ab214810), anti-PAD2 (1:1000, Proteintech, 12,110–1-AP) and anti-actin (1:1000, Abcam, ab-8227). The primary antibodies were detected with HRP-conjugated secondary antibodies and were exposed to ECL reagents to determine the presence or absence of PAD2 and PAD4 proteins (Fig. 2c).

Breeding trials
Seven-week old virgin mice were paired in the following ‘male x female’ matings: DKOxDKO, DKOxWT, WTxDKO or WTxWT (n = 5–6 pairs per group). Pairs were monitored daily for 63 days and birth dates, litter sizes, sex ratios, 2-day old pup weights, and weanling weights were recorded. Statistical analyses were carried out using Microsoft Excel and Social Science Statistics calculators for unpaired Student’s t-test, ANOVA, $\chi^2$ and Goodness of Fit tests with significance set at $P = 0.05$ [24].

Growth and development
Male weanlings were housed singly (to avoid intracage dominance issues), weighed and monitored daily for preputial separation as previously described [25]. Growth curves are provided in Supplemental Fig. S2 (Additional file 2). Mice were euthanized for tissue harvest at ages 46, 48, 50 and 90 days old. At each of these time points, five mice were euthanized by CO$_2$ inhalation and blood was collected by cardiac puncture, allowed to clot at room temperature for 90 minutes, spun at 2000 g for 15 minutes, and the serum was snap frozen and saved for hormone analysis. Serum testosterone, Follicle Stimulating Hormone (FSH), and Lutenizing Hormone (LH) levels were quantified in duplicate by ELISA at the University of Virginia Ligand Assay Core. Testes, epididymis, vas-deferens, seminal vesicles and spleen were harvested and one testis was immediately snap frozen for RNA analysis. The remaining tissues were fixed in 10% formalin for preliminary histological evaluation. Results were analyzed with unpaired t-tests with significance set at $P = 0.05$.

Histological evaluation
Testis, epididymis, vas deferens, seminal vesicle and splenic tissues were collected at 90 days from 5 animals from each of the following strains: Wild-type (WT, FVB/NJ), P2KO, P4KO, and DKO. Collected tissues were fixed
in 10% formalin solution, embedded in paraffin, sectioned at 5 μm, and stained with hematoxylin and eosin (H&E). Initial evaluation revealed epididymis, vas deferens, seminal vesicles, and spleen within normal limits based on previously published observations [26, 27], therefore, only testis sections were evaluated further. The noted changes were scored on a scale of 0 to 3 according to the following criteria: 0 = absent to affecting less than 5% of the tissue; 1 = mild change, affecting 5–25% of the tissue; 2 = moderate change, affecting 25–50% of the tissue; 3 = severe change, affecting > 50% of the tissue (Table S1, Additional file 3).

**RNA sequencing**

Mouse testes were dissected from four-month old mice, two per strain (WT, P2KO, and DKO), and snap-frozen immediately following euthanasia. Total RNA extraction was performed using TRI reagent (Molecular Research Center, Inc. OH) according to the manufacturer's protocol. The RNA concentration and purity were measured by Nanodrop and Qubit (Thermo Scientific, USA).

RNA-seq experiments were performed in the Transcriptional Regulation & Expression Facility (TREx) at Cornell University. RNA integrity was confirmed on a Fragment Analyzer (Agilent) and RNAseq libraries were prepared using the NEB Ultra II Directional RNA library Prep kit (New England Biolabs), with 1 μg total RNA input and initial poly(A) selection. Illumina sequencing was performed on a NovaSeq to generate at least 20 M 2 × 150 paired end reads per sample. The raw fastq reads were first processed with the Trim Galore package to trim for low quality reads, noisy short fragments, and adapter sequence [28]. The filtered reads were then aligned to the GRCm38 reference genome (mm10) with ENSEMBL annotations via STAR using parameters [−outSAMstrandField intronMotif, −outFilterIntronMotifs RemoveNoncanonical, −outSAMtype BAM SortedByCoordinate, −quantMode GeneCounts] [29]. Differential gene expression analysis was performed by DESeq2 [30, 31], with an FDR cut-off of 0.05 and a Benjamini-Hochberg adjusted P value (p-adj) < 0.05 to establish significance. A heatmap and hierarchical clustering dendrogram of differentially expressed genes was produced using Morpheus [32]. Venn diagrams were produced with BioVenn [33].

Gene ontology classification analysis was performed using DAVID v6.8, a web-based bioinformatics resource for functional genomics analysis to identify biological processes, molecular functions, and cellular components [34, 35]. Two hundred and forty-six genes were identified as uniquely upregulated in DKO testes compared to WT. Two hundred and thirty-eight of these genes were identified in the DAVID database and used for subsequent analysis.

**RESULTS and DISCUSSION**

**Generation of Padi2/Padi4 double knockout mice**

Our strategy for generating the Padi2/Padi4 DKO mouse line is shown in Fig. 1a. Padi2-null males and
females were bred to generate Padi2-null zygotes and these embryos were then injected with a Padi4 sgRNA construct and transferred to wild type (FVB/NJ) recipient females to generate founder pups. The Padi4 sgRNA construct was designed to target Exon 1 of the Padi4 gene (Fig. 1b). In total, 39 founders were born, with 13 CRISPR-edited founders being identified by heteroduplex PCR, subcloning, and Sanger sequencing. All of the edited founders were heterozygous mutants, with seven of these founders having a frame-shift mutation. Following back breeding to P2KO, crossing the heterozygous F1 offspring, and genotyping successive generations, one homozygous DKO strain was established and selected for further characterization. This mutant mouse line contained a four-nucleotide deletion in Exon 1 of Padi4 (Fig. 1c) and a predicted premature stop codon (Fig. 1d).

Validation of the DKO mutant line is shown in Fig. 2. We first confirmed that P2KO and DKO mice lacked Padi2 transcripts by RT-PCR analysis of salivary gland (Fig. 2a). We next tested whether the Padi4 sgRNA targeted site in DKO mice contained a deleted sequence by performing PCR analysis of genomic DNA and then separating the DNA fragments on high percentage polyacrylamide gels. Results showed that the DKO amplicon displayed a reduced molecular weight when compared to the P2KO and WT amplicons (Fig. 2b), suggesting that DKO mice contained the targeted deletion, as was shown by Sanger sequencing of the Padi4 locus (Fig. 1c). As expected, no amplicon was observed in P4KO mice. The above results suggested that DKO mice lacked both Padi2 and Padi4 transcripts. We then performed Western blot analysis of WT, P2KO, P4KO and DKO spleen lysates to test if the DKO mice also lacked PAD2 and PAD4 protein. We probed the protein lysates with anti-PADI2 antibodies and found that, while the antibody was reactive with appropriately sized ~75 kDa bands in the WT and P4KO lysates, the antibody did not react with similarly sized bands in the P2KO and DKO mice (Fig. 2c, Additional file 1). Likewise, the anti-PADI4 antibody was reactive with ~75 kDa bands in the WT and P2KO lysates but was not reactive with similarly sized bands in the P4KO and DKO lysates (Fig. 2c, Additional

---

**Fig. 3** Breeding phenotype of Padi2/Padi4 double knockout mice. a In controlled breeding trials, DKO pairs (n=6) took longer than WT pairs (n=7) to have their first litter. When paired with WT mates, DKO males (n=12) took longer than DKO females (n=10) to have their first litter and had fewer pup-producing pairs (data trending, but not significant, one-tailed Fisher’s Exact Test, P = 0.19). b Unsexed pups from the breeding trial litters were weighed at two days post-partum, and showed that DKO pups were smaller than pups of either SKO strain, and significantly smaller than WT pups (one-tailed t-test, *P = 0.004). c Male DKO are significantly smaller than both SKO and WT mice at weaning (ANOVA, pw=0.02, post-hoc one-tailed t-test with WT, **P = 0.003). d Male DKO weanlings are visibly smaller and less developed than SKO and WT. Growth curves are provided in Supplemental 2)
These results indicate that the Padi2/Padi4 DKO strain does not express mature PAD2 and PAD4 proteins. Lastly, we found by RT-PCR that the transcripts of Padi1 and Padi3 continue to be expressed in our DKO mice, indicating that the observed phenotype was due to the disruption of Padi2 and Padi4 and that the other Padi loci remain intact (Fig. 2d).

**Effect of Padi2/Padi4 DKO on fertility parameters**

In order to begin testing for links between PADs and reproductive function, we first performed a controlled breeding trial to test whether a range of reproductive parameters were affected by DKO. Seven-week old mice were paired in 4 mating categories (WTxWT, DKOxDKO, DKOxWT and WTxDKO) and monitored daily for 63 days. Results showed that, although not statistically significant, DKOxDKO pairs tend to lag behind WTxWT pairs in the time taken to have their first litter (Fig. 3a). To identify which sex may be responsible for this reproductive delay, we bred DKO males with WT females and DKO females with WT males, and the trend towards decreased fertility remains more apparent for DKO males than for females (Fig. 3a).

With respect to the offspring produced during the breeding trials in this report, we found that the sex ratio of homozygous DKO offspring was skewed (0.85
male:female) but did not deviate significantly from the expected equal ratio ($\chi^2$ test, $n=243$, $P=0.22$), and that the average DKO litter size was the same as WT mice (two-tailed $t$-test, $n=4$, $P=0.5$). We also observed that unsexed 2-day old DKO pups from these same litters weighed significantly less than WT pups (Fig. 3b, $n=4$ litters per strain, $P=0.004$) and that DKO male weanlings weighed significantly less than WT mice at all ages (Fig. 3c, $n=21,45$, $P=0.003$; Fig. S2, Additional file 2). Taken together, results from these studies suggest that loss of both PAD2 and PAD4 suppresses fertility and affects offspring weight. Previous studies have shown that pup weight is also commonly reduced in sub-fertile mouse strains, including androgen receptor knockout (ARKO) mice [36] which is relevant to the research reported here. Given the growing links between PADs and hormone signaling, we predicted that the effect of DKO on both fertility and pup weight was due to disrupted hormone signaling in these mice.

**Effect of Padi2/Padi4 DKO on pubertal onset**

Pubertal onset is thought to be primarily driven by increased testosterone production in males and one well-established external marker of pubertal development in rodents is preputial separation (PS) [25, 37, 38]. Therefore, as a further test of the hypothesis that hormone signaling is disrupted in DKO males, we documented the timing of PS. Results show that DKO males took an average of 3.6 days longer than WT or SKO males to undergo PS (31.2 vs 27.6 days: ANOVA, $P<0.0001$, Fig. 4a,b). Given that the timing of pubertal onset has been repeatedly, yet inconsistently, linked with obesity [39, 40], and been shown to differ between sexes within the same species/strain [41], we asked whether the delayed puberty in DKO males could be a side-effect of their smaller size at weaning. This does not appear to be the case, as DKO males are significantly heavier than WT and SKO at time of PS (ANOVA, $P=0.0002$, Fig. 4c), and the mean weight of males, regardless of strain, was the same at day 27, which is the average day of PS in WT and SKO (ANOVA, $P<0.0001$, Fig. 4d). Preputial separation is known to be an androgen-dependent process [38, 42], strongly linked to hormone signaling along the hypothalamic-pituitary-gonadal (HPG) axis [43, 44]. These results further support the hypothesis that hormone signaling may be altered in DKO males. Additionally, these observations suggest that PAD2 and PAD4 play an important role in androgen-driven sexual development in males.

**Effect of Padi2/Padi4 DKO on serum hormone levels**

As a more direct test of the hypothesis that hormone levels are altered in DKO mice, we next measured serum testosterone (T), luteinizing hormone (LH), and follicle stimulating hormone (FSH) in WT and DKO males. Results showed that levels of T, LH, and FSH differed significantly between DKO and WT at multiple timepoints ($n=5$ per time point). Although highly variable, serum testosterone levels were lower in DKO males than WT males at all time-points, most significantly at day 48 ($P=0.05$, Fig. 5). In contrast, FSH and LH levels were statistically similar between DKO and WT at earlier time points, but at day 50 both hormones were significantly higher in DKO sera ($P<0.03$). Although it is difficult to infer signaling responses from this data due to use of serum from different individual mice at each time point rather than sequential levels from the same mice across time, we were encouraged by the observation that serum T levels were consistently lower in DKO mice regardless of age, and that LH and FSH differed significantly between strains. Importantly, studies with ARKO mice also found that serum T levels are lower in mutant mice compared to WT mice [36]. Given this observation,
our findings lend support to the prediction that PAD enzymes play a role in androgen signaling in vivo.

**Effect of Padi2/Padi4 DKO on testis size and histology**

**Testis size**

Hormone signaling within the HPG axis not only regulates pubertal onset, but also regulates body growth [41] and testis size [45, 46]. As a further test for potential associations between PADs and hormone signaling, we next investigated whether the total body weight and testis weight was altered in 90-day old adult DKO mice. Results showed that, while there was no difference in total body weight between the WT ($m = 27.4$ g) and DKO ($m = 27.4$ g, $n = 5$, two-tailed t-test, $P = 1$), both absolute testis weight ($P = 0.002$) and the gonadosomatic index (testis weight as a percent of body weight; $n = 5$, one-tailed t-test, $**P = 0.037$) were significantly lower in DKO mice (Fig. 6a,b). Yeh et al. found that both pup size and testis weight are reduced in AR knockout mice [36], and our finding that DKO testes are significantly smaller than WT testes in adults fits well with the hypothesis that PADs play a role in androgen signaling in males.

**Testis histology**

The observation that DKO testes are smaller than WT testes raised the possibility that testicular histology may also be defective in DKO males. To test this hypothesis, FFPE sections of adult testes were stained with H&E and scored for cellular morphology by a board-certified pathologist (Table S1, Additional file 3). Results of this analysis found that there were variable degrees of germ cell apoptosis in the DKO testes when compared to WT testes, with spermatogonia and spermatocytes being the most significantly affected (Fig. 6c-f). More specifically, apoptosis (mild/moderate grade) in spermatocytes (Fig. 6d) was noted in 5 out of 5 DKO mice compared to only 2 out of 5 WT samples. Apoptosis (mild grade) of spermatogonia (Fig. 6e) was noted in 4 out of 5 DKO mice testes compared to only 1 out of 4 WT mice. All five DKO testes also displayed moderate grade residual bodies (Fig. 6f) when compared with WT testes, which only displayed mild grade residual bodies. Sertoli, Leydig cells and interstitium were overall unremarkable. The increased rate of apoptosis and residual bodies did not appear to result in a decrease in sperm production with the lumen of most tubules being lined with histomorphologically unremarkable elongated spermatids and spermatozoa. Interestingly, in ARKO mice, spermatogenesis was arrested at the pachytene stage of meiosis and there was an increase in apoptotic-like bodies within the tubules [36] suggesting that androgen signaling is critical for normal spermatogenesis. Taken together, these results support the hypothesis that PAD2/4 signaling may play a role in androgen signaling-mediated spermatogenesis.
Effect of Padi2/Padi4 DKO on gene expression in the testis

In order to begin investigating whether PADs are associated with specific signaling pathways in the testis, and to more directly test the hypothesis that PAD2/4 play a role in regulating AR target gene expression, we next carried out RNA-Seq analysis of adult WT, P2KO, and DKO testes. Results show that 22 genes were upregulated and 19 genes were downregulated in P2KO samples when compared to WT samples (FDR cut-off 0.05, \( p\)-adj < 0.05). Additionally, we found that 263 genes were upregulated and 140 genes were down-regulated in the DKO samples compared to WT samples (FDR cut-off 0.05, \( p\)-adj < 0.05). Seventeen of the 22 genes that were significantly upregulated in the P2KO samples were also upregulated in the DKO samples. A comparison of upregulated genes is shown in Fig. 7a, with the complete lists of differentially expressed genes (DEGs) provided in Tables S2 and S3 (Additional files 4 and 5). Two hundred and forty-six genes that were uniquely upregulated in DKO testes were then subjected to DAVID gene ontology analysis. Of the 246 genes, 238 were identified in the mouse database and these genes were categorized into three domains: Cellular Components, Molecular Functions, and Biological Processes (Table S4, Additional file 6). Analysis of the Biological Processes domain finds that a majority of the DEGs are involved in reproductive functions (Fig. 7b), thus supporting the phenotypic traits we observed. In addition, analysis of the Molecular Function domain finds that nearly all of the DEGs appear to be involved in either nucleic acid binding or protein phosphorylation (Fig. 7c), thus further supporting the hypothesis that PADs play a role in regulating gene transcription. We next generated a hierarchical dendrogram and heatmap showing the top 100 most significantly up- and downregulated genes using summary counts over all pairwise tests of WT, P2KO, and DKO samples (FDR cut-off 0.05, \( p\)-adj < 0.05; Fig. 8; Table S5, Additional file 7). Results show that there is a good correlation in gene expression levels between replicates for each experimental group. Additionally, the gene expression profile for the DKO samples is distinctly different from that of the WT samples, while there are some overlapping expression patterns when comparing the DKO and P2KO samples. We next narrowed this pool down to 41 transcripts that showed at least a 2-fold difference between strains for further investigation of their known activities. For this analysis, we used The Jackson Laboratory’s Mouse Genome Informatics (MGI) databases [47, 48] and we reviewed the current literature. Of these 41 transcripts, 15 were identified as lncRNAs, 20 were from protein coding genes, and 6 were undescribed or pseudogenes.
lncRNAs are generally known to be involved in transcriptional regulation through either binding DNA directly or changing methylation patterns on chromatin. Alternatively lncRNAs can directly interact with other chromatin modifiers to recruit or deflect their action on transcription [49, 50]. One lncRNA worth mentioning here, *Snhg12*, has been linked to regulation of the cell cycle and promotion of the Epithelial-Mesenchymal Transition in embryogenesis [51]. In addition, *Snhg12* has been shown to promote cell proliferation and inhibit apoptosis in multiple cancers [52], including testosterone-sensitive prostate cancer [53]. Although we do not propose a mechanism, the almost 3-fold decrease in *Snhg12* levels in our DKO mice suggests loss of this factor may have played a significant role in the increased apoptosis and atypical residual bodies that are seen in Fig. 6.

The 20 protein coding genes showing more than a 2-fold change in expression between DKO and WT included multiple members of two important gene families. First, the Kallikreins are a family of serine peptidases, many of which have been linked to AR expression and progression of androgen sensitive prostate cancer cells [54]. Perhaps the best-known member of this family is prostate-specific antigen (KLK3), whose expression is mainly induced by androgen and is transcriptionally regulated by the androgen receptor [55]. Additionally, the kallikrein gene locus is highly responsive to steroid hormones, having at least 14 functional HREs in this region. In fact, many researchers use kallikreins as markers of hormone receptor activity [56]. In our DKO mice, *Klk21*, *Klk24* and *Klk27* are increased 3-fold compared to WT, and these three kallikreins have been shown to be expressed exclusively in Leydig cells and be responsive to testosterone [57]. Additionally, these 3 kallikreins are upregulated in the FOXa3 KO mouse model which shows severe testicular degeneration, increased gonadal apoptosis and decreased fertility [57]. The second over-represented group in our DKO mice are Zinc-finger proteins, a diverse family generally known as regulators of gene expression. Six Zinc-finger proteins are differentially expressed in our DKO mouse testes, two of which are of particular interest here. *Zfp982* has previously been shown to be involved in cell lineage differentiation in embryogenesis [58] and the 12-fold decrease in levels...
of this factor in our DKO mice may have significantly disrupted developmental processes. Zfp979 (also known as Ssm1b) initiates DNA methylation and inhibits transcription in undifferentiated embryonic stem cells as well as in adult murine germ cells [59]. The 20-fold decrease of Ssm1b seen in our DKO testes could allow expression of a multitude of proteins detrimental to early development and germ cell maturation.

Within the remaining differentially expressed coding genes, several stand out as relevant to our discussion for their potential roles in steroid signaling and the HPG axis. Runx3 is decreased 6-fold in our DKO testes. This factor has been shown to regulate steroidogenesis and gonadal development in female mice [60]. Whether it acts similarly in male mice is currently unknown. Mutations in Spry4, which is upregulated 3-fold in our DKO testes, have been implicated in incomplete sexual maturation and infertility due to decreased GnRH activity in human males [61]. Sdc3 (upregulated 12-fold) is considered a regulator of obesity and has been proposed as a modulator of gonadal steroid function [62]. And finally, altered levels of Mrto4 in Balb/C mice (upregulated 3 fold in our DKO) have been linked to disruptions in spermatogenesis, fertility and testosterone levels in mice [63]. These findings further support our hypothesis that PADs play an important role in regulating gene expression in the testis, and more specifically, in regulating AR-mediated gene expression.

Conclusions
Our previous work with PAD2 and PAD4 in breast cancer cell lines has found that both of these PAD isozymes appear to regulate ER target gene expression via citrullination of histone residues at ER binding sites. More recent studies have shown that PAD2 also appears to facilitate androgen receptor target gene expression in prostate cancer cells via similar mechanisms. Together, these observations suggest that PAD2 and PAD4 may represent key mediators of hormone signaling in mammals. While these in vitro findings are intriguing, an important next step in linking PADS with hormone signaling is demonstrating that the phenomenon also occurs at the organissal level. While our Padi2 and Padi4 SKO mouse models have failed to show a reproductive phenotype, outcomes from our Padi2/ Padi4 DKO studies provide a series of clear associations between PADS and hormone signaling and, to our knowledge, this study is the first to make such genetic links using animal models.

We predict that the phenotypic effects of DKO that we have observed in this study are due to the lack of PAD2 and PAD4 activity in the testis. Our DKO mice described here exhibit several phenotypic traits (delayed puberty, small offspring and decreased serum testosterone) that are characteristic of other sub-fertile strains, including a number of AR knockout mouse models [64]. Since PAD2 and PAD4 have previously been implicated in interactions with estrogen and androgen receptors, it is not unexpected to see reproductive defects in these mice. However, our additional finding of abnormal serum testosterone, LH and FSH levels indicates a wider reaching disruption of the HPG axis with implications for more than just reproductive fitness.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12958-022-01018-w.

Acknowledgements
The authors acknowledge the excellent skills and technology provided by Cornell’s Stem Cell & Transgenic Core Facility to create our double knockout mice. We also thank the Baker Institute husbandry technicians for the outstanding care of the animals used in this research.

Authors’ contributions
Experimentation was conceived and conducted by KLS, C. Mukai, BAA and SAC. Breeding and phenotype analysis by KLS and SAC. Histological scoring by EAD and SN. RNA sequencing and analysis by JKG, AET, and FA, with visualization by C. Mittal and KLS. All authors read and approved the final manuscript.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Availability of data and materials
The datasets supporting the conclusions of this article will be available upon publication in NCBI’s Gene Expression Omnibus (GEO) repository (GSE194034, https://www.ncbi.nlm.nih.gov/geo/). Padi2/Padi4 double knockout mice are available from the corresponding author upon reasonable request, and in accordance with Cornell University’s Material Transfer Agreement.

Declarations
Ethics approval and consent to participate
All animal procedures were approved by Cornell University’s Animal Care and Use Committee (IACUC protocol #2007–0115) and are in compliance with the US National Research Council’s Guide for the Care and Use of Laboratory
Animals, the US Public Health Service’s Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals.

Consent for publication
Not applicable.

Competing interests
All authors declare that they have no competing interests.

Author details
1 Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA. 2Department of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA. 3Transcriptional Regulation and Expression Facility, Department of Biomedical Sciences, Cornell University, Ithaca, NY, USA.

Received: 5 May 2022 Accepted: 23 September 2022 Published online: 12 October 2022

References
1. Wang S, Wang Y. Peptidylarginine deiminases in cetrullination, gene regulation, health and pathogenesis. Biochim Biophys Acta. 2013;1829(10):1126–35.
2. Witalison EE, Thompson PR, Hofseth LJ. Protein arginine deiminases and associated Citrullination: physiological functions and diseases associated with dysregulation. Curr Drug Targets. 2015;16(7):700–10.
3. Vossenaar ER, Zandman AJW, van Venrooij WJ, Pruijn GJM. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays. 2005;27(11):1106–18.
4. Valsini G, Gerardi MC, Iannuccelli C, Pacucci VA, Pendolino M, Shoenfeld I, et al. Proteomics. Tissue-based map of the human proteome. Science. 1992;267(1):520–5.
5. Dong S, Zhang Z, Takahara H. Estrogen-enhanced Peptidylarginine deiminase type IV gene (PADI4) expression in MCF-7 cells is mediated by estrogen receptor-α-promoted Transfactors activator Protein-1, nuclear factor-Y, and Sp1. Mol Endocrinol. 2007;21(7):1617–29.
6. Pontén J, Iström K, Uhlen M. The Human Protein Atlas—a tool for pathology. J Pathol. 2008;216(4):387–93.
7. Takahara H, Kusubata M, Tsuchida M, Koshioka T, Tagami S, Sugawa K. Expression of peptidylarginine deiminase in the uterine epithelial cells of mouse is dependent on estrogen. J Biol Chem. 2012;287(1):520–5.
8. Uhlen M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):120419.
9. Mani SK, Mermelstein PG, Tetel MJ, Anesseti G. Convergence of multiple mechanisms of steroid hormone action. Horm Metab Res. 2002;34(8):339–44.
10. Hagiwara T, Nakashima K, Hirano H, Senshu T, Yamada M. Deimination of arginine residues in Nucleophosmin/B23 and histones in HL-60 granulocytes. Biochem Biophys Commun. 2002;290(3):979–83.
11. Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, Leonelli L, et al. Human PAD4 regulates histone arginine methylation levels via Demethylimination. Science. 2004;306(5694):279–83.
12. Wang L, Song G, Zhang X, Feng T, Pan J, Chen W, et al. PAD2-mediated Citrullination promotes prostate Cancer progression. Cancer Res. 2017;77(21):5755–68.
13. Zhang X, Bolt M, Guertin MJ, Chen W, Zhang S, Cherrington BD, et al. Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 cetrullination facilitates estrogen receptor a target gene activation. Proc Natl Acad Sci. 2012;109(33):13361–6.
14. Guertin MJ, Zhang X, Anguish L, Kim S, Varticovski L, Liu JT, et al. Targeted H3R26 Deimination specifically facilitates estrogen receptor binding by modifying nucleosome structure. Plos Genet. 2014;10(9):e1004613.
15. Tsuji-Hosokawa A, Kashimada K, Kato T, Ogawa Y, Nomura R, Takasawa K, et al. Peptidyl arginine deiminase 2 (Padi2) is expressed in Sertoli cells in a specific manner and regulated by SOX9 during testicular development. Sci Rep. 2018;8:13263.
16. Sahadevan M, Kumar PG. Peptidyl arginine deiminase 2 (PADI2) is expressed in post-meiotic germ cells in the mouse testis and is localized heavily on the Acrosomal region of spermatozoa. J Endocrinol Reprod. 2021;25(1):37–49.
17. Briot J, Simon M, Melchin MC. Deimination, intermediate filaments and associated proteins. Int J Mol Sci. 2020;21(22):8746.
18. Guide-for-the-Care-and-use-of-laboratory-animals.pdf. Available from: https://grants.nih.gov/grants/olaw/Guide-for-the-Care-and-use-of-laboratory-animals.pdf. Cited 2022 Apr 18.
19. Mouse Colony Management Software: Access the SoftMouse.NET app on your mobile Android and iPad tablets. Available from: https://www.softmouse.net/. Cited 2022 Apr 18.
20. Hansen GM, Markesich DC, Burnett MB, Zhu Q, Dionne KM, Richter LJ, et al. Large-scale gene trapping in C57BL/6N mouse embryonic stem cells. Genome Res. 2008;18(10):1670–9.
21. Singh P, Schimenti JC, Bolcun-Filas E. A mouse Geneticist’s practical guide to CRISPR applications. Genetics. 2015;199(1):1–15.
22. Singh P, Schimenti JC. The genetics of human infertility by functional interrogation of SNPs in mice. Proc Natl Acad Sci. 2015;112(33):10431–6.
23. Zhu X, Xu Y, Yu S, Lu L, Ding M, Cheng J, et al. An efficient genotyping method for genome-modified animals and human cells generated with CRISPR/Cas9 system. Sci Rep. 2014;4(1):6420.
24. Social Science Statistics. Available from: https://www.soscistatistics.com/. Cited 2022 Apr 18.
25. Hoffmann RM. Determination of reproductive competence by confirming pubertal onset and performing a fertility assay in mice and rats. JoVE J Vis Exp. 2018;140:e58352.
26. Creasy D, Bube A, de Rijk E, Kandori H, Kuwahara M, Masson P, et al. Proliferative and nonproliferative lesions of the rat and mouse male reproductive tissue. Toxicol Pathol. 2012;40(6_suppl):405–1215.
27. Meistrich ML, Hess RA. Assessment of Spermatogenesis Through Staging of Seminiferous Tubules. In: Carrell DT, Aston KI, editors. Spermatogenesis. Totowa: Humana Press; 2013. p. 299–307. (Methods in Molecular Biology, vol. 927). Available from: http://link.springer.com/10.1007/978-1-62703-038-0_27. Cited 2021 Nov 18.
28. Babraham Bioinformatics - Trim Galore. Available from: https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/. Cited 2022 Apr 18.
29. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR, ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):11–21.
30. Love MJ, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(2):550.
31. Varett H, Brillot-Guéguen L, Coppée JY, Dillies MA. SARTools: a DESeq2- and EdgeR-based R pipeline for comprehensive differential analysis of RNA-seq data. Plos One. 2016;11(6):e0157022.
32. Morpheus. Available from: https://software.broadinstitute.org/morpheus/. Cited 2022 Apr 18.
33. Hulsen T, de Vlieg J, Alkema W. BioVenn – a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics. 2008;9(1):488.
34. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13.
35. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
36. Yeh S, Tsai MY, Xu Q, Mu XM, Lardy H, Huang KE, et al. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A. 2002;99(21):13498–503.
37. Gaytan F, Bellido C, Aguilar R, Aguilar E. Balano-preputial separation model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A. 2002;99(21):13498–503.
38. Reinehr T, Hoffmann E, Rothermel J, Lehrnij T, Binder G. Characteristic dynamics of height and weight in preschool boys with constitutional delay of growth and puberty or hypogonadotropic hypogonadism. Clin Endocrinol. 2019;91(3):424–31.
40. Amaro F, Chiarelli F. Growth and puberty in children with inflammatory bowel diseases. Biomedicines. 2020;8(11):E458.

41. Corre C, Shinoda G, Zhu H, Coussinier DL, Crossman C, Bellissimo C, et al. Sex-specific regulation of weight and puberty by the Lin28/let-7 axis. J Endocrinol. 2016;228(3):179–91.

42. Yoshimura S, Yamaguchi H, Konno K, Ohsawa N, Noguchi S, Chisaka A. Observation of preputial separation is a useful tool for evaluating endocrine active chemicals. J Toxicol Pathol. 2005;18(3):141–57.

43. Handelsman DJ. Testosterone, Spermatogenesis, and unravelling the mysteries of puberty. Endocrinology. 2020;161(9):bjaaj120.

44. Keene DE, Suecucun MO, Bostwick MG, Chandrashekar V, Bartke A, Kopchick JJ. Puberty is delayed in male growth hormone receptor gene—disrupted mice. J Androl. 2002;23(5):661–8.

45. Huh K, Nah WH, Xu Y, Park MJ, Gye MC. Effects of recombinant human growth hormone on the onset of puberty, Leydig cell differentiation, spermatogenesis and hypothalamic Kiss1 expression in immature male rats. World J Mens Health. 2021;39(2):381–8.

46. Miyaso H, Nagahori K, Takano K, Omotetebara T, Kawata S, Li ZL, et al. Neonatal maternal separation causes decreased numbers of sertoli cell, spermatogenic cells, and sperm in mice. Toxicol Mech Methods. 2021;31(2):116–25.

47. Baldarelli RM, Smith CM, Finger JH, Hayamizu TF, McCright U, Xu J, et al. The mouse gene expression database (GXD): 2021 update. Nucleic Acids Res. 2020;49(D1):D924–31.

48. Blake JA, Baldarelli R, Kadin JA, Richardson JE, Smith CL, Bult CJ. Mouse genome database (MGD): knowledgebase for mouse–human comparative biology. Nucleic Acids Res. 2020;49(D1):D981–7.

49. Ali T, Grote P. Beyond the RNA-dependent function of LncRNA genes. Elife. 2020;9:1025–36. https://doi.org/10.7554/eLife.60583.

50. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96–118.

51. Zhou F, Sun Y, Chi Z, Gao Q, Wang H. Long noncoding RNA SNHG12 promotes the proliferation, migration, and invasion of trophoblast cells by regulating the epithelial–mesenchymal transition and cell cycle. J Int Med Res. 2020;48(6):0300065520922339.

52. Tamang S, Acharya V, Roy D, Sharma R, Aryaa A, Sharma U, et al. SNHG12: an LncRNA as a potential therapeutic target and biomarker for human Cancer. Front Oncol. 2019;9:901.

53. Chen Z, Qi T, Qin XP, Wang J, Huang ZS, Hu XY, et al. Long noncoding RNA SNHG12 promotes prostate tumor occurrence and progression via AKT regulation. Biomed Res Int. 2020;2020:8812923.

54. Matin F, Jeev V, Shrivastav S, Cristino AS, Panchadassaram J, Clements JA, et al. MicroRNA-3162-5p-mediated crosstalk between Kallikrein family members including prostate-specific antigen in prostate Cancer. Clin Chem. 2019;65(6):771–80.

55. Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem. 2004;93(2):233–41.

56. Lawrence MG, Lai J, Clements JA. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended Kallikrein locus. Endocr Rev. 2010;31(4):407–46.

57. Matsui H, Takahashi T. Mouse testicular Leydig cells express Klk21, a tissue Kallikrein that cleaves fibronectin and IGF-binding Protein-3. Endocrinol. 2001;142(11):4918–29.

58. Dietrich JE, Panavate L, Gunther S, Wennekamp S, Griner AC, Pigge A, et al. Venus trap in the mouse embryo reveals distinct molecular dynamics underlying specification of first embryonic lineages. EMBO Rep. 2015;16(8):1005–21.

59. Ratnam S, Bozek G, Martin T, Gallagher SJ, Payne CJ, Storb U. Ssm1b expression and function in germ cells of adult mice and in early embryos. Mol Reprod Dev. 2017;84(7):596–613.

60. Ojima F, Saito Y, Tsuyciya Y, Oogami M, Fukamachi H, Inagaki K, et al. Runx3 regulates folliculogenesis and steroidogenesis in granulosa cells of immature mice. Cell Tissue Res. 2019;375(3):743–54.

61. Indirli R, Cangiano B, Profka E, Mantovani G, Persani L, Arosio M, et al. A rare SPRY4 gene mutation is associated with anosmia and adult-onset isolated hypogonadotropic hypogonadism. Front Endocrinol. 2019;10:781.

62. Schuring AN, Lutz F, Tuttelman F, Gromoll J, Kiesel L, Götze M. Role of syndecan-3 polymorphisms in obesity and female hyperandrogenism. J Mol Med. 2009;87(12):1241.